West Pharmaceutical Services INC Form 4 insider transactions

Robert W. Mcmahon, SVP & Chief Financial Officer of West Pharmaceutical Services Inc, reported multiple transactions in common stock on August 11, 2026.

Janet Brutschea Haugen, a Director at West Pharmaceutical Services Inc., reported transactions involving restricted stock units and phantom stock units.

Shane Alden Campbell, SVP of Proprietary Segment at West Pharmaceutical Services, reported transactions involving restricted stock units and common stock.

West Pharmaceutical Services Director Paolo Pucci was granted 791 restricted stock units as part of director compensation.

West Pharmaceutical Services Director Douglas A. Michels acquired 791 restricted stock units as part of director compensation.

West Pharmaceutical Services Director Stephen H. Lockhart acquired 791 shares of common stock via a restricted stock unit grant.

Director Myla Lai Goldman acquired 791 restricted stock units of West Pharmaceutical Services, Inc. as part of director compensation.

West Pharmaceutical Services director Deborah L. Keller was granted 791 restricted stock units as part of equity compensation.

Director Molly Joseph acquired 791 restricted stock units in West Pharmaceutical Services, Inc. as part of an equity grant.

West Pharmaceutical Services Director Janet B. Haugen acquired 791 restricted stock units as part of director compensation.

West Pharmaceutical Services Director Robert F. Friel acquired 791 shares of common stock via a restricted stock unit grant.

Director William F. Feehery acquired 791 restricted stock units of West Pharmaceutical Services, Inc. as part of director compensation.

West Pharmaceutical Services Director Mark A. Buthman acquired 791 restricted stock units as part of an equity grant.

Annette Favorite, Sr. VP & Chief HR Officer at West Pharmaceutical Services, reported transactions involving common stock and stock options.

Chad Winters, VP and Chief Accounting Officer of West Pharmaceutical Services, reports transactions involving common stock and stock options.

West Pharmaceutical Services Director Janet Haugen reported the acquisition of phantom stock units and restricted stock units, vesting in 2026.

Norman D. Finch Jr., SVP, GC & Corporate Secretary of West Pharmaceutical Services Inc., reported the acquisition of restricted stock units and stock options.

West Pharmaceutical Services CEO Eric Green received awards of 6,986 restricted stock units and options to purchase 16,630 shares of common stock.

Annette F. Favorite, Sr. VP & Chief HR Officer at West Pharmaceutical Services Inc., received grants of restricted stock units and stock options.

West Pharmaceutical Services SVP Shane Campbell reported the acquisition of 1,131 restricted stock units and 2,691 stock options under a pre-arranged plan.

West Pharmaceutical Services' Chief Financial Officer, Robert W. McMahon, was granted 3,082 restricted stock units and 7,337 stock options on March 1, 2026.

West Pharmaceutical Services SVP Rodolphe Poussot received grants of restricted stock units and stock options.

Chad Winters, VP and Chief Accounting Officer of West Pharmaceutical Services Inc., was granted 340 restricted stock units and 808 stock options.

A West Pharmaceutical Services executive converted restricted stock units into common stock and sold a portion to cover tax obligations.

West Pharmaceutical Services VP & Treasurer Charles Witherspoon converted restricted stock units into common stock and subsequently disposed of shares for tax obligations.

West Pharmaceutical Services VP, Chief Accounting Officer Chad Winters converted restricted stock units into common stock and sold a portion for tax obligations.

Rodolphe Jean Poussot, SVP of Strategy & Corporate Development at West Pharmaceutical Services, reported the conversion of restricted stock units into common stock and a subsequent sale for tax obligations.

Charles Witherspoon, VP & Treasurer of West Pharmaceutical Services Inc., reported the vesting of performance stock units and subsequent tax-related share disposition.

West Pharmaceutical Services VP, Chief Accounting Officer Chad Winters reported the vesting of performance stock units and subsequent tax-related share disposition.

WEST PHARMACEUTICAL SERVICES INC's President, CEO, and Board Chair, Eric Mark Green, reported the acquisition of common stock through PSU vesting and RSU conversion, alongside related tax-driven dispositions.